Cancer clinical trials in the region Bourgogne-Franche-Comté
217 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Breast cancer
#NCT05512364
#2022-501453-36-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Surgery
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3
Breast cancer
#NCT06966700
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
HR Positive
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Radiotherapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Surgery
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Radiotherapy
Hormone therapy
9 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT05918302
#2022-502154-13-00
Required histologic types
Neuroendocrine tumor/carcinoma other than SCLC
Required histologic sub types
Neuroendocrine tumor/carcinoid
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
2
8 recruiting sites
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Breast cancer
#NCT05633654
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Chemotherapy
Radiotherapy
Required previous treatments at advanced or metastatic stage
Surgery
Chemotherapy
Radiotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Immunotherapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
Antibody Drug Conjugates (ADC)
16 recruiting sites
Gilead Sciences
Phase 3
Cervical / Vulvar / Vaginal cancer
#NCT05581121
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma
Adenocarcinoma
Adenosquamous carcinoma
Required FIGO stages
Stage III
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Radiotherapy
24 recruiting sites
Institut Claudius Regaud
Phase 3
Head and neck cancer
#NCT04892173
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Surgery
Chemotherapy
Radiotherapy
Radiochemotherapy
15 recruiting sites
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
Lymphoma
#NCT06717347
#2024-515566-13-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
14 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06868277
#2024-517780-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
12 recruiting sites
AstraZeneca
Phase 3
Lung cancer
#NCT06472245
#2023-509340-10-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
29 recruiting sites
OSE Immunotherapeutics
Phase 3
Breast cancer
#NCT05894239
#2022-502046-28-00
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
5 recruiting sites
Hoffmann-La Roche